Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pituitary ACTH Hypersecretion 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Neoplasms 1Hypertension 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Diabetes Mellitus, Type 2 1Cushing Syndrome 1Carcinoma, Pancreatic Ductal 1Adrenocortical Carcinoma 1Adrenal Cortex Neoplasms 1Adenocarcinoma 1ACTH Syndrome, Ectopic 1

Interventions

Oxaliplatin 9Capecitabine 9Fluorouracil 7pembrolizumab 6Paclitaxel 6Leucovorin 6Cisplatin 5zolbetuximab 4trastuzumab deruxtecan 3enzalutamide 3durvalumab 3cemiplimab 3Trastuzumab 3Gemcitabine 3Docetaxel 3fludarabine 2darolutamide 2Taxes 2Ramucirumab 2Radiotherapy, Image-Guided 2Radiosurgery 2Pemetrexed 2Nivolumab 2Irinotecan 2Cyclophosphamide 2Carboplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2vistusertib 1tucatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma × relacorilant × 90 days × Clear all
NCT07259317 2026-04-23

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Corcept Therapeutics

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡